Key result
A cocktail of phosphorodiamidate morpholino oligomers effectively induced dose-dependent skipping of dystrophin exons 45-55 and rescued dystrophin protein in myotubes transdifferentiated from DMD patient fibroblasts.
Why the study?
Does a cocktail of PMOs induce dystrophin exons 45-55 skipping and protein rescue in myotubes transdifferentiated from DMD patient fibroblasts?
Does a cocktail of PMOs induce dystrophin exons 45-55 skipping and protein rescue in myotubes transdifferentiated from DMD patient fibroblasts?
Answers are grounded in this paper and cite their sources.
A cocktail of PMOs successfully induced dystrophin exons 45-55 skipping and protein rescue in transdifferentiated DMD patient myotubes, validating this in vitro model and supporting the feasibility of multi-exon skipping therapy.
Antisense-mediated exon skipping has made significant progress as a therapeutic platform in recent years, especially in the case of Duchenne muscular dystrophy (DMD). Despite FDA approval of eteplirsen-the first-ever antisense drug clinically marketed for DMD-exon skipping therapy still faces the significant hurdles of limited applicability and unknown truncated protein function. In-frame exon skipping of dystrophin exons 45-55 represents a significant approach to treating DMD, as a large proportion of patients harbor mutations within this "hotspot" region. Additionally, patients harboring dystrophin exons 45-55 deletion mutations are reported to have exceptionally mild to asymptomatic phenotypes. Here, we demonstrate that a cocktail of phosphorodiamidate morpholino oligomers can effectively skip dystrophin exons 45-55 in vitro in myotubes transdifferentiated from DMD patient fibroblast cells. This is the first report of substantive exons 45-55 skipping in DMD patient cells. These findings help validate the use of transdifferentiated patient fibroblast cells as a suitable cell model for dystrophin exon skipping assays and further emphasize the feasibility of dystrophin exons 45-55 skipping in patients.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2018) studied Duchenne muscular dystrophy (DMD) (n=3). Phosphorodiamidate morpholino oligomer (PMO) cocktails was evaluated on Dose-dependent production of exons 45-55 skipped transcripts and rescue of dystrophin protein. A cocktail of phosphorodiamidate morpholino oligomers effectively induced dose-dependent skipping of dystrophin exons 45-55 and rescued dystrophin protein in myotubes transdifferentiated from DMD patient fibroblasts.
Synapse has enriched 10 related papers. Consider them for comparative context: